ArticleNature communications2025
Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease.
Brandon Zimmerman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this papercites it